Abstract:IL-10-producing Tr1 cells promote tolerance but their contributions to tolerogenic memory are unclear. Using 10BiT mice that carry a Foxp3-eGFP reporter and stably express CD90.1 following IL-10 production, we characterized the spatiotemporal dynamics of Tr1 cells in a house dust mite model of allergic airway inflammation. CD90.1+Foxp3-IL-10+ Tr1 cells arise from memory cells and rejoin the tissue-resident memory T-cell pool after cessation of IL-10 production. Persistent antigenic stimulation is necessary to … Show more
“…Since Tr1 cells are induced in the periphery (29) and are therefore antigen-experienced, they are thought to be memory CD4 + T cells and behave as such. Evidence to the contrary was introduced in an airway allergy model in which Tr1-like cells substantially reduced airway inflammation in an acute inflammatory setting but showed no role during re-challenge despite being present as resident memory cells (42).…”
Section: Classification Of Tr1 Cells and Mechanisms Of Their Inductionmentioning
confidence: 99%
“…Since Tr1 cells are induced in the periphery ( 29 ) and are therefore antigen-experienced, they are thought to be memory CD4 + T cells and behave as such. Evidence to the contrary was introduced in an airway allergy model in which Tr1-like cells substantially reduced airway inflammation in an acute inflammatory setting but showed no role during re-challenge despite being present as resident memory cells ( 42 ). The conclusion that Tr1-like cells did not contribute to tolerogenic memory was primarily based on the finding that inflammation was not enhanced in the recall response upon the in vivo depletion of IL-10-producing T cells.…”
Section: Classification Of Tr1 Cells and Mechanisms Of Their Inductionmentioning
Type 1 regulatory T (Tr1) cells, in addition to other regulatory cells, contribute to immunological tolerance to prevent autoimmunity and excessive inflammation. Tr1 cells arise in the periphery upon antigen stimulation in the presence of tolerogenic antigen presenting cells and secrete large amounts of the immunosuppressive cytokine IL-10. The protective role of Tr1 cells in autoimmune diseases and inflammatory bowel disease has been well established, and this led to the exploration of this population as a potential cell therapy. On the other hand, the role of Tr1 cells in infectious disease is not well characterized, thus raising concern that these tolerogenic cells may cause general immune suppression which would prevent pathogen clearance. In this review, we summarize current literature surrounding Tr1-mediated tolerance and its role in health and disease settings including autoimmunity, inflammatory bowel disease, and infectious diseases.
“…Since Tr1 cells are induced in the periphery (29) and are therefore antigen-experienced, they are thought to be memory CD4 + T cells and behave as such. Evidence to the contrary was introduced in an airway allergy model in which Tr1-like cells substantially reduced airway inflammation in an acute inflammatory setting but showed no role during re-challenge despite being present as resident memory cells (42).…”
Section: Classification Of Tr1 Cells and Mechanisms Of Their Inductionmentioning
confidence: 99%
“…Since Tr1 cells are induced in the periphery ( 29 ) and are therefore antigen-experienced, they are thought to be memory CD4 + T cells and behave as such. Evidence to the contrary was introduced in an airway allergy model in which Tr1-like cells substantially reduced airway inflammation in an acute inflammatory setting but showed no role during re-challenge despite being present as resident memory cells ( 42 ). The conclusion that Tr1-like cells did not contribute to tolerogenic memory was primarily based on the finding that inflammation was not enhanced in the recall response upon the in vivo depletion of IL-10-producing T cells.…”
Section: Classification Of Tr1 Cells and Mechanisms Of Their Inductionmentioning
Type 1 regulatory T (Tr1) cells, in addition to other regulatory cells, contribute to immunological tolerance to prevent autoimmunity and excessive inflammation. Tr1 cells arise in the periphery upon antigen stimulation in the presence of tolerogenic antigen presenting cells and secrete large amounts of the immunosuppressive cytokine IL-10. The protective role of Tr1 cells in autoimmune diseases and inflammatory bowel disease has been well established, and this led to the exploration of this population as a potential cell therapy. On the other hand, the role of Tr1 cells in infectious disease is not well characterized, thus raising concern that these tolerogenic cells may cause general immune suppression which would prevent pathogen clearance. In this review, we summarize current literature surrounding Tr1-mediated tolerance and its role in health and disease settings including autoimmunity, inflammatory bowel disease, and infectious diseases.
“…Rather, Th17 cells are first converted to exTh17 cells during the inflammatory process. Among the surface markers of exTh17, in addition to CD161, CCR6, which maintains Th17, CXCR3 is also expressed [ Jung, S et al, 2023 ; Yadava, K et al, 2019 ]. Although these exTh17 cells no longer secrete IL-17, they still retain some inflammatory properties, such as the production of cytokines including IL-2, TNF, IFN-γ, and GM-CSF [Yadava, K et al, 2019].…”
Section: Cd4
+
Trm May Originate From Th17 and Tregmentioning
“…9a-c). This suggested that CAR expression and function in Teff cells is increased in response to inflammation, analogous to Tr1 cell dynamics in vivo 28 . Using an orthologous approach to induce intestinal inflammation in wild type or CAR-deficient mice—soluble anti-CD3 injection 23 — we confirmed that CAR was required for anti-CD3 ( i.e ., inflammation)-induced IL-10 upregulation by endogenous effector and regulatory T cell subsets in the siLP, but not the spleen, and was dispensable for steady-state IL-10 expression in T cells from unmanipulated mice (Extended data Figure 9d-f).…”
Bile acids (BAs) are fundamental lipid emulsifying metabolites synthesized in hepatocytes and maintained via enterohepatic circulation between the liver and ileum. Because they are lipophilic, BAs can be cytotoxic in enterohepatic tissues and several nuclear receptors are now recognized for suppressing BA toxicity in hepatocytes and enterocytes. By contrast, it remains unclear how mucosal immune cells protect themselves from high BA concentrations in the small intestine. We previously showed that CD4+ T effector (Teff) cells upregulate expression of the xenobiotic transporter, MDR1, in the ileum to prevent BA toxicity and suppress Crohns disease-like small bowel inflammation. Here, we identify the BA- and xenobiotic-sensing nuclear receptor, constitutive androstane receptor (CAR/NR1I3), as a regulator of MDR1 expression in mucosal T cells. CAR expression increased in Teff cells during mucosal inflammation and promoted large-scale transcriptional reprogramming in the small intestine lamina propria (siLP). CAR-dependent gene expression in siLP Teff cells shared features with that in hepatocytes, and involved the induction of detoxifying enzymes and transporters, but also the key anti-inflammatory cytokine, Il10. CAR-deficiency in Teff cells exacerbated, whereas pharmacologic CAR activation suppressed, BA-driven ileitis in T cell-reconstituted Rag-/- mice. In addition, bile, though not major BA species per se, enhanced CAR transcriptional activity, and CAR-dependent gene expression in human CD4+ Th cells was restricted to a4+b7 integrin+CCR9+ Teff cells licensed for small bowel homing. These data implicate CAR in prompting a hepatocyte-like transcriptional response in mucosal T cells that detoxifies BAs and enforces small bowel immune homeostasis. Pharmacologic activation of this program may offer an unexpected strategy to treat small bowel Crohns disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.